
Richard L White Jr

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/746312/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Regression in melanoma is significantly associated with a lower regional recurrence rate and better recurrenceâ€free survival. Journal of Surgical Oncology, 2022, 125, 229-238.	1.7	1
2	Single surgeon versus coâ€surgeon bilateral mastectomy: Comparing outcomes and costs based on health economic modeling from the perspective of the hospital system. Journal of Surgical Oncology, 2022, 126, 239-246.	1.7	1
3	Sentinel Lymph Node Biopsy Is Prognostic in Thickest Melanoma Cases and Should Be Performed for Thick Melanomas. Annals of Surgical Oncology, 2021, 28, 1007-1016.	1.5	15
4	Regression is significantly associated with outcomes for patients with melanoma. Surgery, 2021, 170, 1487-1494.	1.9	7
5	Factors predicting survival in thick melanoma: Do all thick melanomas have the same prognosis?. Surgery, 2020, 168, 518-526.	1.9	9
6	Radiographic Surveillance of Patients with Non-BRCA1/2 Pathogenic Variants. Annals of Surgical Oncology, 2020, 27, 2248-2254.	1.5	3
7	ASO Author Reflections: Is Sentinel Lymph Node Biopsy Necessary in Patients with Ductal Carcinoma In Situ with Microinvasion Diagnosed on Core Biopsy?. Annals of Surgical Oncology, 2020, 27, 733-734.	1.5	1
8	Management of Cancer Surgery Cases During the COVID-19 Pandemic: Considerations. Annals of Surgical Oncology, 2020, 27, 1717-1720.	1.5	180
9	Recurrence rates and relapse-free survival for patients with completely resected melanoma: Contemporary experience Journal of Clinical Oncology, 2020, 38, e22080-e22080.	1.6	0
10	Cemiplimab as first intervention for patients with locally advanced cutaneous squamous cell carcinoma Journal of Clinical Oncology, 2020, 38, 10065-10065.	1.6	2
11	Ductal Carcinoma In Situ with Microinvasion on Core Biopsy: Evaluating Tumor Upstaging Rate, Lymph Node Metastasis Rate, and Associated Predictive Variables. Annals of Surgical Oncology, 2019, 26, 3874-3882.	1.5	7
12	Recurrence of Melanoma After a Negative Sentinel Node Biopsy: Predictors and Impact of Recurrence Site on Survival. Annals of Surgical Oncology, 2019, 26, 2254-2262.	1.5	26
13	Completion lymphadenectomy for a positive sentinel node biopsy in melanoma patients is not associated with a survival benefit. Journal of Surgical Oncology, 2019, 119, 1053-1059.	1.7	12
14	Does Neoadjuvant Chemotherapy for Breast Cancer Affect Lymph Node Harvest Rates?. American Surgeon, 2019, 85, 690-694.	0.8	0
15	Microsatellitosis in Patients with Melanoma. Annals of Surgical Oncology, 2019, 26, 33-41.	1.5	11
16	Rate of radial scars by core biopsy and upgrading to malignancy or high-risk lesions before and after introduction of digital breast tomosynthesis. Breast Cancer Research and Treatment, 2019, 173, 23-29.	2.5	26
17	Re: Using the 21â€gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial. <i>Journal of Surgical Oncology</i> 2017;115(8):917–923 Journal of Surgical Oncology, 2018, 118, 722-722.	1.7	1
18	Stratifying SLN incidence in intermediate thickness melanoma patients. American Journal of Surgery, 2018, 215, 699-706.	1.8	26

RICHARD L WHITE JR

#	Article	IF	CITATIONS
19	<i>Rationale for Mastectomy after Neoadjuvant Chemotherapy</i> . American Surgeon, 2018, 84, 126-132.	0.8	9
20	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. , 2018, 6, 44.		59
21	Using the 21â€gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial. Journal of Surgical Oncology, 2017, 115, 917-923.	1.7	72
22	ls pelvic sentinel node biopsy necessary for lower extremity and trunk melanomas?. American Journal of Surgery, 2017, 213, 921-925.	1.8	4
23	Reporting of mitotic rate in cutaneous melanoma: A study using the national cancer data base. Journal of Surgical Oncology, 2017, 115, 281-286.	1.7	6
24	Changes in margin reâ€excision rates: Experience incorporating the "no ink on tumor―guideline into practice. Journal of Surgical Oncology, 2017, 116, 1040-1045.	1.7	20
25	Letter response: Reporting of mitotic rate in cutaneous melanoma. Journal of Surgical Oncology, 2017, 116, 960-960.	1.7	Ο
26	Pediatric and Adolescent Melanoma: A National Cancer Data Base Update. Annals of Surgical Oncology, 2016, 23, 4058-4066.	1.5	41
27	Surgical Decision Making in the BRCA-Positive Population: Institutional Experience and Comparison with Recent Literature. Breast Journal, 2016, 22, 35-44.	1.0	34
28	Clinical utilities and biological characteristics of melanoma sentinel lymph nodes. World Journal of Clinical Oncology, 2016, 7, 174.	2.3	20
29	Margin reâ€excision and local recurrence in invasive breast cancer: A cost analysis using a decision tree model. Journal of Surgical Oncology, 2015, 112, 443-448.	1.7	46
30	Breast cancer detection in axillary sentinel lymph nodes: the impact of the method of pathologic examination. Human Pathology, 2014, 45, 2497-2501.	2.0	5
31	Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option?. Journal of Kidney Cancer and VHL, 2014, 1, 74-83.	1.0	25
32	Incidence and survival of patients with TON1 breast cancers Journal of Clinical Oncology, 2014, 32, 56-56.	1.6	0
33	Screening in the high-risk populations: Stage of breast cancer when detected by combination imaging with MRI and mammogram Journal of Clinical Oncology, 2013, 31, 44-44.	1.6	Ο
34	The follow-up sought after diagnosis of a BRCA-1 or BRCA-2 mutation Journal of Clinical Oncology, 2012, 30, 57-57.	1.6	0
35	Cancer Immunotherapy. Surgical Oncology Clinics of North America, 2011, 20, 531-554.	1.5	3
36	Sentinel Lymph Node Biopsy After Neo-adjuvant Chemotherapy in Breast Cancer. Breast Journal, 2011, 17, 71-74.	1.0	9

RICHARD L WHITE JR

#	Article	IF	CITATIONS
37	Factors Predictive of the Status of Sentinel Lymph Nodes in Melanoma Patients from a Large Multicenter Database. Annals of Surgical Oncology, 2011, 18, 3593-3600.	1.5	78
38	Cryoablative therapy in breast cancer: No. Journal of Surgical Oncology, 2008, 97, 483-484.	1.7	3
39	Update on the NSABP and ACOSOG breast cancer sentinel node trials. American Surgeon, 2004, 70, 420-4.	0.8	48